Fatigue in Multiple Sclerosis
9
2
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
22%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis
Non-invasive Brain Stimulation in Multiple Sclerosis Fatigue
MS Fatigue and tDCS on Fatigue in Multiple Sclerosis
Sexual Dysfunction in Women With Multiple Sclerosis (MS)
Testing the Effects of Methylphenidate on Multiple Sclerosis
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis